Virbac (CHIX:VIRPP) Total Liabilities: €789 Mil (As of Dec. 2025)


CHIX:VIRPP Virbac SA CHIX:VIRPP
95 GF Score
Price €334.00
GF Value €350.14
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Virbac Total Liabilities?

Virbac CHIX:VIRPP 95 Total Liabilities is €789 Mil as of Dec. 2025. GuruFocus rates CHIX:VIRPP with a GF Score™ of 95/100 and a GF Value™ of €350.14 (Fairly Valued). The stock has 2 warning signs investors should review.

Virbac's Total Liabilities for the quarter that ended in Dec. 2025 was €789 Mil.

Virbac's quarterly Total Liabilities declined from Dec. 2024 (€805.12 Mil) to Jun. 2025 (€750.28 Mil) but then increased from Jun. 2025 (€750.28 Mil) to Dec. 2025 (€789.19 Mil).

Virbac's annual Total Liabilities increased from Dec. 2023 (€545.81 Mil) to Dec. 2024 (€805.12 Mil) but then declined from Dec. 2024 (€805.12 Mil) to Dec. 2025 (€789.19 Mil).

Virbac Total Liabilities Historical Data

* Premium members only.

The historical data trend for Virbac's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Virbac Total Liabilities Chart

Virbac Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 476.36 494.33 545.81 805.12 789.19

Virbac Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 545.81 801.99 805.12 750.28 789.19
CHIX:VIRPP
95GF Score
Virbac SA CHIX:VIRPP
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Virbac Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Virbac's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=516.31+(174.177+63.267
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+21.168+14.263)
=789

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=1914.167-1124.982
=789

Virbac's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=516.31+(174.177+63.267
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+21.168+14.263)
=789

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=1914.167-1124.982
=789

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €789 Mil mean?
Virbac (CHIX:VIRPP) has a Total Liabilities of €789 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Virbac and its competitors.
Is Virbac's Total Liabilities too high?
Virbac's current Total Liabilities is €789 Mil. Overall, Virbac has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Virbac's Total Liabilities compare to LLY and JNJ?
Virbac's Total Liabilities of €789 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Virbac and its competitors. Virbac's current Total Liabilities is €789 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virbac stock overvalued right now?
Based on GuruFocus' analysis, Virbac (CHIX:VIRPP) is currently considered Fairly Valued. The stock's GF Value™ is €350.14, compared to a current price of €334.00 — trading 4.6% below its estimated fair value. The current Total Liabilities is €789 Mil. Virbac's overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Virbac (CHIX:VIRPP), the current Total Liabilities is €789 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Virbac (CHIX:VIRPP) Overvalued in 2026?

Based on GuruFocus' analysis, Virbac stock appears to be undervalued. The current stock price of €334.00 is trading 4.6% below its estimated GF Value™ of €350.14. GuruFocus considers Virbac to be Fairly Valued.

Key valuation signals for CHIX:VIRPP:

  • Total Liabilities: €789 Mil
  • GF Value™: €350.14 vs. price of €334.00 (4.6% below fair value)
  • GF Score™: 95/100 with 2 warning signs

No single metric tells the full story. See the CHIX:VIRPP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Virbac Business Description

Address 13e rue, 1ere avenue 2065, LID - BP 27, Carros, FRA, 06511
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, and it also has its presence in Europe, North America, Far East Asia, India, Africa & Middle East (IMEA), Pacific, and Latin America.
95GF Score

Get the complete analysis for CHIX:VIRPP

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€334.00
Price
€350.14
GF Value